These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24050512)

  • 21. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea.
    Kang KK; Lee DH; Oh DH; Yoon H; Shin CM; Park YS; Kim N; Jung HC
    World J Gastroenterol; 2014 Jun; 20(22):6932-8. PubMed ID: 24944485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility.
    Cheon JH; Kim SG; Kim JM; Kim N; Lee DH; Kim JS; Jung HC; Song IS
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1590-5. PubMed ID: 16928222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Esomeprazole, minocycline, metronidazole and bismuth as first-line and second-line regimens for Helicobacter pylori eradication.
    Song ZQ; Zhou LY
    J Dig Dis; 2016 Apr; 17(4):260-7. PubMed ID: 26946480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line
    Kim SE; Roh JH; Park MI; Park SJ; Moon W; Kim JH; Jung K; Heo JJ
    Korean J Gastroenterol; 2019 Jan; 73(1):26-34. PubMed ID: 30690955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
    Zheng Q; Pan Y; Zhang L; Xiao SD
    Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.
    Chen Q; Zhang W; Fu Q; Liang X; Liu W; Xiao S; Lu H
    Am J Gastroenterol; 2016 Dec; 111(12):1736-1742. PubMed ID: 27670603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate.
    Yoon H; Kim N; Lee BH; Hwang TJ; Lee DH; Park YS; Nam RH; Jung HC; Song IS
    Helicobacter; 2009 Oct; 14(5):77-85. PubMed ID: 19751431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection.
    Yoon H; Kim N; Kim JY; Park SY; Park JH; Jung HC; Song IS
    J Gastroenterol Hepatol; 2011 Jan; 26(1):44-8. PubMed ID: 21175792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
    Chung SJ; Lee DH; Kim N; Jung SH; Kim JW; Hwang JH; Park YS; Lee KH; Jung HC; Song IS
    Hepatogastroenterology; 2007 Jun; 54(76):1293-6. PubMed ID: 17629092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection.
    Nista EC; Candelli M; Zocco MA; Cazzato IA; Cremonini F; Ojetti V; Santoro M; Finizio R; Pignataro G; Cammarota G; Gasbarrini G; Gasbarrini A
    Aliment Pharmacol Ther; 2005 May; 21(10):1241-7. PubMed ID: 15882245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ranitidine versus colloidal bismuth subcitrate in combination with amoxicillin and metronidazole for eradicating Helicobacter pylori in patients with duodenal ulcer.
    Carpintero P; Blanco M; Pajares JM
    Clin Infect Dis; 1997 Nov; 25(5):1032-7. PubMed ID: 9402352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole.
    Gisbert JP; Gisbert JL; Marcos S; Grávalos RG; Carpio D; Pajares JM
    Aliment Pharmacol Ther; 1999 Oct; 13(10):1311-6. PubMed ID: 10540045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori.
    Yang J; Zhang Y; Fan L; Zhu YJ; Wang TY; Wang XW; Chen DF; Lan CH
    Am J Gastroenterol; 2019 Mar; 114(3):437-445. PubMed ID: 30807294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG
    Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
    Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
    Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled trial.
    Kaviani MJ; Malekzadeh R; Vahedi H; Sotoudeh M; Kamalian N; Amini M; Massarrat S
    Eur J Gastroenterol Hepatol; 2001 Aug; 13(8):915-9. PubMed ID: 11507355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study.
    Onal IK; Gokcan H; Benzer E; Bilir G; Oztas E
    Clin Res Hepatol Gastroenterol; 2013 Dec; 37(6):642-6. PubMed ID: 23796974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial.
    Calvet X; Ducons J; Guardiola J; Tito L; Andreu V; Bory F; Guirao R;
    Aliment Pharmacol Ther; 2002 Jul; 16(7):1261-7. PubMed ID: 12144575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.